首页> 外文期刊>Clinical cardiology. >Modifying Clopidogrel Maintenance Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance
【24h】

Modifying Clopidogrel Maintenance Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance

机译:根据血管扩张剂刺激的磷酸蛋白磷酸化指数修改氯吡格雷维持剂量可改善氯吡格雷抵抗性患者的临床疗效

获取原文
       

摘要

Background:Despite dual antiplatelet therapy, the rate of major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) remains high. Ex vivo tests of clopidogrel resistance can predict MACE after PCI. The purpose of this study is to evaluate the clinical impact of adjusting phosphorylation analysis in patients with clopidogrel resistance undergoing PCI.Hypothesis:We hypothesized that VASP-guided clopidogrel maintenance doses, compared to fixed doses, improved clinical outcome.Methods:This monocentric, prospective, randomized study was performed on 306 patients undergoing PCI. Patients were randomized to a control group (n = 156) and to a vasodilator-stimulated phosphoprotein (VASP)-guided group (n = 150). In the VASP-guided group, patients received adjusted maintenance doses of clopidogrel to obtain platelet reactivity index (PRI) of 50% during 1 year after PCI. The primary endpoint was the rate of MACE. The secondary endpoints were major and minor bleeding.Results:All patients completed the PCI procedure and 298 patients completed follow-up. The control and VASP-guided groups had similar demographic, clinical, and angiographic characteristics. In the VASP-guided group, PRI was significantly decreased (from 72.1% ± 11.4% to 27.7% ± 8.4%; P = 0.001) in 128 patients (87.1% of all participants). During the 1-year follow-up, 14 MACEs were recorded in the VASP-guided group and 30 MACEs were recorded in the control group (9.3% vs 20.4%, respectively; P = 0.008). There was no difference in the rate of major and minor bleeding in the VASP-guided group compared with the control group (12.9% vs 16.6%; P = 0.06).Conclusions:Modifying clopidogrel maintenance doses according to platelet reactivity monitoring decreases the rate of MACE after PCI without increasing bleeding in patients with clopidogrel resistance during 1-year follow-up. ? 2011 Wiley Periodicals, Inc.This project was sponsored by Science and Technology Commission of Shanghai Municipality (No. SK08-6). The authors have no other funding, financial relationships, or conflicts of interest to disclose.
机译:背景:尽管采用双重抗血小板治疗,但经皮冠状动脉介入治疗(PCI)后主要不良心血管事件(MACE)的发生率仍然很高。氯吡格雷抵抗性的离体试验可以预测PCI后的MACE。假设:假设:我们假设,与固定剂量相比,VASP指导的氯吡格雷维持剂量可改善临床疗效。方法:该单中心,前瞻性,对306例接受PCI的患者进行了随机研究。患者被随机分为对照组(n = 156)和血管舒张剂刺激的磷蛋白(VASP)引导组(n = 150)。在VASP指导的组中,患者在PCI后1年内接受了调整剂量的氯吡格雷维持剂量,以使血小板反应性指数(PRI)低于50%。主要终点是MACE发生率。次要终点为大出血和小出血。结果:所有患者均完成了PCI程序,并有298例患者接受了随访。对照组和VASP指导的人群具有相似的人口统计学,临床和血管造影特征。在VASP指导的组中,128例患者(占所有参与者的87.1%)的PRI显着降低(从72.1%±11.4%降至27.7%±8.4%; P = 0.001)。在1年的随访期间,VASP指导组记录了14个MACE,对照组记录了30个MACE(分别为9.3%和20.4%; P = 0.008)。 VASP引导组的大出血和小出血率与对照组无差异(12.9%比16.6%; P = 0.06)。结论:根据血小板反应性监测调整氯吡格雷维持剂量可降低氯吡格雷维持率。在1年的随访期间,氯吡格雷抵抗性患者PCI后无增加出血的MACE。 ? 2011威利期刊有限公司,该项目由上海市科学技术委员会主办(No. SK08-6)。作者没有其他资金,财务关系或利益冲突需要披露。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号